Migraine in women statistics: the 3-to-1 sex gap in numbers

She sat in my office with her sunglasses still on. Mid-thirties, two kids, a job she could not afford to miss. For three days each month, right as her period started, the left side of her head pulsed so hard she vomited if she stood too quickly. Outside those days she was fine. She had been told it was "just stress" and "just her period" for years. Her PHQ-9 was normal. Her blood pressure was normal. Her migraine diary was not.

Migraine is one of the largest sex-disparity conditions in clinical medicine. In U.S. population studies, women develop migraine at roughly three times the rate of men. The gap opens after puberty, peaks in the reproductive years, and narrows after menopause. Hormones do not explain every attack, but they shape timing, severity, treatment choices, and stroke risk in ways that still get undercounted in primary care.

This article pulls together the numbers reporters and clinicians actually quote: prevalence by sex, menstrual migraine share, aura-related stroke risk, what happens in pregnancy and perimenopause, disability ranking, the diagnosis and prevention gap, and what changed once CGRP-targeted drugs arrived.

How common migraine is in women versus men

The cleanest U.S. figure for ICHD-defined migraine still comes from the American Migraine Prevalence and Prevention study. Lipton and colleagues mailed a validated questionnaire to 120,000 households and analyzed 162,576 people ages 12 and older. The one-year period prevalence of migraine was 11.7% overall: 17.1% in women and 5.6% in men. That is the 3-to-1 ratio you see in nearly every briefing document for a reason. It is large and stable, measured with diagnostic criteria rather than a single self-report item.

CDC data tell a parallel story with a slightly different question. In the 2018 National Health Interview Survey, adults were asked whether they had a severe headache or migraine in the past three months. Women answered yes 20.1% of the time; men, 10.6%. Among women ages 18-44, the rate reached 25.5%, then fell with age to 7.6% at 75 and older. For men in the same age bands, the figures were 12.3% and 4.0%. The sex gap is present at every adult age group the CDC published.

Prevalence is not the same as severity. In AMPP, 31.3% of people with migraine had three or more attacks per month, and 53.7% reported severe impairment or the need for bed rest during attacks. Women are overrepresented in both the count of cases and the disability those cases produce. That is why migraine shows up so forcefully in global disability rankings even though it does not kill people the way stroke or cancer does.

A note on the "3-to-1" shorthand: depending on survey year and case definition, female-to-male ratios land between roughly 2-to-1 (CDC severe headache/migraine item) and about 3-to-1 (AMPP ICHD migraine). Both are real. Adult women carry most of the burden, and it is heaviest when work and family responsibilities collide in midlife.

Menstrual migraine and the hormonal link

Menstrual migraine is a distinct pattern: attacks that cluster on day 1 ± 2 of menstruation in at least two of three cycles. Estrogen withdrawal before menses is the leading explanation. Those attacks often last longer, respond less cleanly to usual acute drugs, and disrupt work more than non-menstrual attacks.

How common is it? Definitions vary. Population studies using stricter ICHD-aligned windows often place menstrually related migraine in the 18%-25% range of women with migraine. Clinic samples run higher. A 2024 analysis of the 2021 U.S. National Health and Wellness Survey, presented at the American Academy of Neurology meeting by Brown, Ailani and colleagues, found that among nearly 20 million women with diagnosed migraine, 6.2 million reported menstrual migraine: 31.0% overall and 52.5% of premenopausal women with migraine. More than half (56.2%) scored moderate-to-severe disability on MIDAS. Only 21.1% reported any migraine prevention.

That last number is the problem. Women who can map attacks to their cycle often leave with another acute prescription and no short-term prevention plan around menses. A period calculator or cycle-length tracker will not diagnose migraine, but a three-cycle diary lining up headache days with bleeding days can change the conversation from "random headaches" to a treatable pattern. Monthly vomiting headaches that force someone into a dark room for 12 hours are not "just PMS."

Migraine with aura, stroke, and cardiovascular risk

Migraine with aura is a minority of migraine, but it is the subtype that changes cardiovascular counseling. Aura means reversible neurologic symptoms (often visual, sometimes sensory or speech-related) that typically build over minutes and resolve. The absolute risk of stroke in a young woman with migraine remains low. The relative risk is not trivial, and it stacks with other factors.

In a nationwide nested case-control analysis of U.S. claims data published in the American Journal of Obstetrics & Gynecology in 2017, Champaloux and colleagues compared women ages 15-49 with first-ever ischemic stroke to matched controls. Compared with women who had neither migraine nor combined hormonal contraceptive use, the adjusted odds ratio for ischemic stroke was 6.1 (95% CI 3.1-12.1) for migraine with aura plus combined hormonal contraceptives, 2.7 for migraine with aura without those contraceptives, 1.8 for migraine without aura plus combined hormones, and 2.2 for migraine without aura without combined hormones. The authors' practical conclusion was blunt: determining migraine type matters when counseling about estrogen-containing contraception.

Separate stroke research presented at the American Heart Association's International Stroke Conference reported that people with migraine with aura were 2.4 times more likely to have an ischemic stroke than people with migraine without aura, with stronger associations for cardioembolic and thrombotic subtypes. Migraine with aura accounted for less than 20% of all migraines in that research summary. That is a reminder that most women with migraine do not carry this specific risk profile, but the ones who do need it named out loud.

CDC and ACOG contraceptive eligibility frameworks treat migraine with aura as a reason to avoid combined hormonal contraceptives in many patients. Progestin-only methods and nonhormonal options remain on the table. For a broader look at how contraception access and medical contraindications interact in practice, see our overview of contraception access and unintended pregnancy statistics. Stroke risk also sits inside the larger picture of heart disease risk in women, where migraine with aura is one of several under-discussed midlife factors.

Relative risks sound alarming; absolute risks in healthy nonsmokers without hypertension are still small. Smoking, uncontrolled blood pressure, and estrogen together is the combination I worry about most.

Pregnancy and the menopause transition

Pregnancy is often kinder to migraine than the years around it. Observational series and reviews show improvement for a majority after the first trimester, especially for migraine without aura. MacGregor summarized that around 60%-70% of women with migraine improve in pregnancy, particularly in the second and third trimesters. Detailed cohorts report improvement in roughly half by the end of the first trimester, climbing above 80% later, with complete remission more common as pregnancy progresses. Migraine with aura is less likely to settle. A minority worsen, and a few present with new migraine in pregnancy. That scenario needs evaluation, not automatic reassurance.

Treatment options shrink in pregnancy. Many preventives and some acute drugs are off the table or used only after risk-benefit discussion. Preconception planning matters: stabilize the pattern before conception when you can, and write down a pregnancy-safe acute plan. Women tracking fertility can pair headache diaries with an ovulation calculator, but medication plans should come from obstetrics and neurology, not an app.

The menopause transition often goes the other direction. Hormonal swings in perimenopause can raise attack frequency even in women who were stable for years. AMPP analyses found that frequent headache (10 or more days per month) was about 50%-60% more common in perimenopausal women (12.2%) and postmenopausal women (12.0%) than in premenopausal women (8.0%). After the final menstrual period, many women with migraine without aura improve as estrogen stabilizes lower. Surgical menopause is less predictable. For related context, see perimenopause symptoms and menopause hormone therapy statistics.

Disability ranking and years lived with disability

Migraine's public-health weight shows up in disability metrics, not mortality. Using GBD 2019 estimates, Steiner and colleagues reported that migraine remained second among the world's causes of years lived with disability and first among young women. In young women, it was also the leading cause of disability-adjusted life years. The authors called the finding profound because migraine causes no premature death. The years lost are years of reduced function during education, early career and childrearing.

WHO's 2025 fact sheet places the problem at population scale: headache disorders affected about 40% of people worldwide, roughly 3.1 billion in 2021, and are more common in females. In Global Health Estimates for 2021, migraine ranked third among causes of neurological DALYs worldwide after stroke and neonatal encephalopathy. WHO also notes a care gap that has barely moved: only a minority of people with headache disorders are appropriately diagnosed and treated, and about half are estimated to self-treat.

IHME communications on GBD 2023 reinforce the sex split. Headache disorders ranked sixth among causes of disability globally in 2023, with age-standardized YLD rates more than twice as high in women (739.9 per 100,000) as in men (346.1 per 100,000). Migraine alone accounted for an estimated 40.9 million YLDs that year and drove nearly 90% of headache-related disability even though tension-type headache is more common. The burden has not meaningfully fallen over three decades.

Disability is not abstract in clinic. It is the teacher who uses half her sick days by March, the nurse working through photophobia because the unit is short-staffed, the mother who cannot drive carpool three mornings a month.

Diagnosis and treatment gaps

Migraine is common and recognizable, yet still mishandled. WHO states that headache disorders have been underestimated, under-recognized and under-treated worldwide, and that lack of knowledge among health-care providers is the principal clinical barrier. In many settings, people with migraine never receive a formal diagnosis or a migraine-specific acute drug.

AMPP quantified the U.S. prevention gap clearly. Expert criteria indicated that prevention should be offered to 25.7% of people with migraine and considered for another 13.1%, about 38.8% together. Only 13.0% reported current use of daily preventive medication. More than half reported severe impairment or bed rest during attacks. The distance between who needs prevention and who gets it is not a rounding error.

The Georgetown analysis of 2021 survey data found the same pattern inside menstrual migraine: high disability, heavy reliance on acute care, prevention in roughly one in five. OTC medication remains default care for many women whose attack frequency already warrants prevention. Part of the gap is specialty access and step-therapy. Part is the habit of treating migraine as a character flaw rather than a neurologic disease.

Diagnosis can be delayed when aura is mistaken for TIA, or chronic migraine is labeled "sinus" for years. Better access to women's health care helps, but migraine still needs specific training; see women's healthcare access disparities. Sleep disruption also feeds attack frequency: covered in sleep disorders and insomnia statistics in women.

CGRP-era treatment and access

For decades, migraine prevention meant borrowing drugs from other specialties: beta-blockers, antiseizure medicines, antidepressants, onabotulinumtoxinA for chronic migraine. Many helped some people. Many were limited by side effects, slow titration, or pregnancy concerns. The calcitonin gene-related peptide (CGRP) pathway changed the menu.

On May 17, 2018, the FDA approved erenumab (Aimovig), the first monoclonal antibody developed specifically to prevent migraine by blocking the CGRP receptor. Amgen's announcement described significant reductions in monthly migraine days in Phase 2 and 3 trials, including in people who had failed prior preventives, and listed a U.S. price of $575 per month ($6,900 per year) at launch. Additional CGRP monoclonal antibodies and gepants followed for acute and preventive use. Clinicians could finally offer migraine-specific prevention rather than only repurposed drugs.

Access did not keep pace. CGRP monoclonal antibodies are brand-name biologics. Commercial plans commonly required failure of two or three older oral preventives first. Monthly costs without assistance remained out of reach for many uninsured and underinsured women. Specialty wait times added months. The American Headache Society later moved toward positioning CGRP-targeted therapies as appropriate first-line options for many patients, but payer policy often still reflects older step-therapy logic.

The CGRP era is real in tertiary headache clinics and uneven elsewhere. A woman with eight migraine days a month, two failed generics, and commercial insurance may get a monoclonal antibody within weeks. A woman with the same disease on Medicaid in a county without a headache specialist may still be cycling through NSAIDs and urgent care. New mechanisms do not automatically close income-based gaps.

What I want patients to take from the CGRP story is permission to escalate. If attacks are frequent, disabling, or breaking through acute treatment, prevention is not a last resort. It is standard care that too few women receive.

Frequently asked questions about migraine in women

How much more common is migraine in women than in men?

In the AMPP study, one-year migraine prevalence was 17.1% in women and 5.6% in men, about a 3-to-1 ratio. CDC NHIS 2018 data on severe headache or migraine in the past three months showed 20.1% of women versus 10.6% of men. The gap is largest in reproductive-age adults and narrows later in life.

What percentage of women with migraine have menstrual migraine?

It depends on definition. Stricter population studies often find menstrually related migraine in roughly one-fifth to one-quarter of women with migraine. A 2021 U.S. National Health and Wellness Survey analysis presented at AAN 2024 reported menstrual migraine in 31% of women with migraine overall and 52.5% of premenopausal women with migraine.

Does migraine with aura increase stroke risk?

Yes, relatively. Champaloux et al. (AJOG, 2017) found about 2.7-fold higher odds of ischemic stroke with migraine with aura alone, rising to 6.1-fold when combined with combined hormonal contraceptives, versus neither factor. Absolute risk in young healthy women remains low, but guidelines often advise against estrogen-containing contraception when aura is present.

Does migraine improve in pregnancy?

For many women, yes. Clinical reviews commonly cite improvement in about 60%-70%, especially after the first trimester and especially for migraine without aura. Detailed cohorts report improvement climbing above 80% in the second and third trimesters. Aura-associated migraine is less likely to remit, and a minority of women worsen or develop new attacks.

Why is migraine ranked so high for disability?

Migraine causes substantial years lived with disability because attacks are common, often severe, and peak in midlife. GBD 2019 analyses ranked migraine second among global causes of YLDs and first among young women. It produces little mortality, so its burden shows up as lost function rather than death counts.

Are CGRP drugs widely available?

They are approved and effective for many patients, starting with FDA approval of erenumab in May 2018, but access remains uneven. High list prices, prior-authorization rules, step therapy through older preventives, and limited specialty access mean many women who could benefit still do not receive CGRP-targeted treatment promptly.